Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

3.87
0.0000
Volume:- -
Turnover:- -
Market Cap:26.56M
PE:-1.08
High:3.87
Open:3.87
Low:3.87
Close:3.87
52wk High:23.43
52wk Low:2.90
Shares:6.86M
Float Shares:6.46M
Volume Ratio:1.39
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5690
EPS(LYR):-7.2500
ROE:-614.05%
ROA:-135.36%
PB:4.86
PE(LYR):-0.53

Loading ...

Plus Therapeutics Receives AMA Pla Code for Cnside® Csf Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

THOMSON REUTERS
·
Apr 07

Plus Therapeutics Inc : Maxim Group Adjusts Target Price to $12 From $37.5 to Reflect 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
Apr 07

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

TIPRANKS
·
Apr 07

Plus Therapeutics enacts 1-for-25 reverse stock split to maintain Nasdaq listing

Reuters
·
Apr 03

Plus Therapeutics secures Highmark coverage for CNSide CSF assay, expands covered lives to 75 million

Reuters
·
Apr 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Apr 02

Plus Therapeutics enacts 1-for-25 reverse stock split to meet Nasdaq $1 bid rule

Reuters
·
Apr 01

Plus Therapeutics announces annual shareholder meeting

Reuters
·
Apr 01

Plus Therapeutics grants inducement awards: options, RSUs covering 600,000 shares

Reuters
·
Apr 01

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 01

BRIEF-Plus Therapeutics Announces Reverse Stock Split

Reuters
·
Mar 31

Plus Therapeutics Inc - Announces 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
Mar 31

Plus Therapeutics director Ronald Asbury Andrews files initial beneficial ownership statement

Reuters
·
Mar 31

Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience

Reuters
·
Mar 26

Press Release: Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

Dow Jones
·
Mar 26

Plus Therapeutics to present CNSide analysis showing 40% leptomeningeal metastases cost reduction at ISPOR 2026

Reuters
·
Mar 19

Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV)

TIPRANKS
·
Feb 26

Plus announces new Category III CPT code for CED used with Reyobiq

TIPRANKS
·
Feb 25

Plus Therapeutics Inc: Are on Track to Complete Enrollment in Phase 2 Recurrent Glioblastoma Trial in 2026

THOMSON REUTERS
·
Feb 25

Plus Therapeutics Announces New Category Iii Cpt Code for Convection-Enhanced Delivery Used With Reyobiq™

THOMSON REUTERS
·
Feb 25